Actimed Therapeutics is a pioneering brand dedicated to revolutionizing the treatment of cachexia, a debilitating wasting disease that is commonly associated with cancer and other chronic illnesses. Our mission is to improve the lives of an underserved and vulnerable patient population by prolonging their life expectancy, enhancing their quality of life, and alleviating the burden for patients, caregivers, and healthcare providers. Unlike any other pharmaceutical product currently available worldwide, Actimed Therapeutics offers a unique approach that targets the underlying biology of cachexia.

Our class of agents aims to reduce catabolism (weight loss), promote anabolism (weight gain and muscle mass retention), combat fatigue, and stimulate appetite. Leading the way in our portfolio is S-pindolol benzoate (ACM-001. 1), a promising compound currently in clinical development specifically for cancer-related cachexia.

Our esteemed founders, Professor Andrew Coats and Professor Stefan Anker, are renowned physicians in the field of cachexia research. Combined with the expertise of our experienced management team and board, Actimed Therapeutics is determined to introduce innovative treatments not only for cancer cachexia but also for amyotrophic lateral sclerosis and other muscle-wasting conditions. With our commitment to advancing healthcare through groundbreaking therapies, Actimed Therapeutics strives to become the world's first globally approved treatment for cancer cachexia, while simultaneously expanding our product portfolio to address the urgent needs of patients with various muscle-wasting conditions